Attili, I.; Fuorivia, V.; Spitaleri, G.; Corvaja, C.; Trillo Aliaga, P.; Del Signore, E.; Asnaghi, R.; Carnevale Schianca, A.; Passaro, A.; de Marinis, F.
Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials. Cancers 2024, 16, 2457.
https://doi.org/10.3390/cancers16132457
AMA Style
Attili I, Fuorivia V, Spitaleri G, Corvaja C, Trillo Aliaga P, Del Signore E, Asnaghi R, Carnevale Schianca A, Passaro A, de Marinis F.
Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials. Cancers. 2024; 16(13):2457.
https://doi.org/10.3390/cancers16132457
Chicago/Turabian Style
Attili, Ilaria, Valeria Fuorivia, Gianluca Spitaleri, Carla Corvaja, Pamela Trillo Aliaga, Ester Del Signore, Riccardo Asnaghi, Ambra Carnevale Schianca, Antonio Passaro, and Filippo de Marinis.
2024. "Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials" Cancers 16, no. 13: 2457.
https://doi.org/10.3390/cancers16132457
APA Style
Attili, I., Fuorivia, V., Spitaleri, G., Corvaja, C., Trillo Aliaga, P., Del Signore, E., Asnaghi, R., Carnevale Schianca, A., Passaro, A., & de Marinis, F.
(2024). Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials. Cancers, 16(13), 2457.
https://doi.org/10.3390/cancers16132457
